Goff, Stephanie L.

Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels

Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 569

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., Parkhurst, M. R., Yossef, R., Lowery, F. J., Jafferji, M. S., et al. (2020) · Journal of Clinical Investigation

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 427

A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers

Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersCAR-T cell therapy research

Cited by 200

Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain

Mikkilineni, L., Natrakul, D. A., Lam, N., Manasanch, E. E., Mann, J., Weissler, K. A., Wong, N., Brudno, J. N., Goff, S. L., Yang, J. C., et al. (2024) · Molecular Therapy

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 16

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Mikkilineni, L., Manasanch, E. E., Natrakul, D., Brudno, J. N., Mann, J., Goff, S. L., Yang, J. C., Lam, N., Maric, I., Stetler-Stevenson, M., et al. (2021) · Blood

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 9